On 8 July 2025, the world’s leading index company, FTSE Russell, recently announced the latest Environmental, Social and Governance (ESG) rating results for Fosun International Limited (HKEX stock code: 00656) (“Fosun International”). In 2025, Fosun International’s FTSE Russell ESG rating was upgraded to 3.9, consistently outperforming the global industry average (2.6) and the national average (2.0), while maintaining its inclusion in the FTSE4Good Index Series for the fourth consecutive years.

The most authoritative corporate governance magazine in the Asia Pacific region, Corporate Governance Asia, has recently presented the 15th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International, were awarded Asia’s Best CEO by the magazine.

Shanghai, China, July 2, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) announces that the company has received the GMP Certificate, issued by the Federal Agency for Medicines and Health Products in Belgium, for the production lines of HLX14, an investigational biosimilar candidate of Prolia^® and Xgeva^® (denosumab), and HLX11, an investigational biosimilar candidate of Perjeta^® (pertuzumab). According to the GMP mutual recognition system among European Union (EU) member states, it marks that the related production lines have met the EU GMP standards. The inspection success, as well as the previous certification by the EMA GMP for Henlius’ self-developed trastuzumab biosimilar HANQUYOU and innovative PD-1 inhibitor serplulimab HANSIZHUANG, reconfirms the company’s longstanding reputation in maintaining quality systems fully compliant with the highest international standards.

Shanghai, China, July 1, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that it had entered into a strategic cooperation agreement with FBD Biologics Limited ("FBD"), a holding subsidiary of HanchorBio. Henlius is granted exclusive rights to develop, manufacture and commercialize HCB101, a SIRPα-Fc fusion protein independently developed by HanchorBio, in China and certain countries and regions in Southeast Asia as well as Middle East and North Africa (MENA), alongside the right of first negotiation (ROFN) for the molecule in Japanese market. Under the terms of the agreement, HanchorBio is eligible to receive a $10 million upfront payment and up to $192 million in potential predetermined milestones, in addition to royalties upon Henlius commercialization in the territory.

In 2025, Club Med, a subsidiary of Fosun Tourism Group, celebrates its 75th anniversary. 75 years ago, Club Med introduced the all-inclusive holiday concept and innovatively launched the G.O (Gentil Organisateurs) and Kids Club, creating a unique vacation lifestyle. Since Fosun's investment in 2010, the brand has undergone a revitalization, opening a new chapter in high-quality global development and earning praise from French President Macron as a "textbook" example of Sino-French cooperation. Currently, Club Med operates nearly 70 resorts in 26 countries and regions worldwide, welcoming over 1.5 million guests annually, with an annual turnover exceeding 2 billion euros.

On 30 June 2025, Corporate Governance Asia presented the 15th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited (“Fosun International”, “Fosun” or the “Group”) (HKEX stock code: 00656) were both honored Asia’s Best CEO. In addition, Fosun International was awarded Sustainable Asia Award 2025, Best Environmental Responsibility Award and Best Corporate Communications Award.

Henlius (2696.HK) announced that its self-developed anti-PD-1 monoclonal antibody (mAb) serplulimab (trade name in Europe: Hetronifly^®) has been approved in both the United Kingdom and India for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Commercialisation in the UK and India will be led by Henlius’ partner Intas and its subsidiary Accord Healthcare.

TEL AVIV and SHANGHAI, June 16, 2025 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, SSE: 600196, HKEX: 02196) today announced that the companies, through their respective subsidiaries, have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Teva’s internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad array of oncology indications.

Recently, Henlius' self-developed anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab, trade name: Hetronifly^® in Europe) has secured approvals in Singapore and Malaysia through its local license holder, KGbio (a subsidiary of PT Kalbe Farma Tbk.), under the trade name Zerpidio^® for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This marks another significant expansion in Southeast Asia following earlier approvals in Indonesia, Cambodia, and Thailand. Under the agreement, serplulimab’s commercialization in Southeast Asia is managed by KGbio, which holds exclusive rights to develop and commercialize the drug for certain indications and therapies across 10 ASEAN countries.